An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Tudorza Pressair

Chemical Nameaclidinium bromide
Dosage FormPowder (inhalation; 400mcg)
Drug ClassAnticholinergics
SystemRespiratory
CompanyAlmirall
Approval Year2012

Indication

  • For the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Last updated on 12/16/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tudorza Pressair (aclidinium bromide) Prescribing Information2019Circassia Pharmaceuticals Inc., Morrisville, NC
Document TitleYearSource
Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD) (review).2018Cochrane Database of Systematic Reviews
Efficacy and safety of aclidinium/formoterol versus tiotropium in COPD: results of an indirect treatment comparison.2016Advances in Therapy